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Summary objective To estimate loss to follow up (LTFU) between initial enrolment and the ﬁrst scheduled
return medical visit of a pre-antiretroviral therapy (ART) care program for patients not eligible for ART.
methods The study was conducted at a public-sector HIV clinic in Johannesburg. We reviewed re-
cords of all patients newly enrolled in the pre-ART care program and not yet eligible for ART between
January 2007 and February 2008. Crude proportions of patients completing their ﬁrst return medical
visit stratiﬁed by patient characteristics were calculated. A modiﬁed-Poisson approach was used to
estimate directly relative risks of returning for their ﬁrst return medical visit within 1 year adjusting for
patient characteristics as potential confounders.
results A total of 356 patients were identiﬁed. Two-thirds had a CD4 count > 350 cells⁄ll (median
[IQR] CD4 = 458 [394, 585]) and were scheduled to return in 6 months for a ﬁrst medical visit. Seventy-
four percent of these patients did not return within one year for this visit. The remaining 36% of all
patients had a baseline CD4 count 251–350 cells⁄ll and were scheduled to return in 3 months. Only 6%
of these patients returned within 4 months; 41% returned within one year. Relative risks were positively
associated with a patient being employed and negatively associated with the baseline CD4 count.
conclusions Given the high rate of LTFU immediately after enroling in pre-ART care, it is clear that
care programs are not expediting the timely initiation of ART. Signiﬁcantly improved adherence to pre-
ART care and monitoring for patients not yet eligible for ART is required for South Africa to achieve its
AIDS strategy goals and reduce the problem of late presentation and initiation of ART.
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Introduction
Most HIV-infected individuals in developing countries
present for HIV⁄AIDS care and treatment late in disease
progression, with very low CD4 counts (Fairall et al.
2008; Rosen et al. 2008; Kigozi et al. 2009; Egger 2007).
‘Late presentation’ is deﬁned as already eligible for
antiretroviral therapy (ART) at ﬁrst presentation to a
treatment site, and, therefore, initiation of ART occurs
well after reaching eligibility. In most developing coun-
tries, the threshold for initiating ART is already low –
typically 200 CD4 cells⁄ll – so presentation at an even
lower CD4 count poses an immediate threat to the
patient’s survival (Egger 2007). Given the typical time
between eligibility based on CD4 counts and actual
initiation of treatment, patients die or are lost to follow
up before they begin therapy (Lawn et al. 2005, 2006;
Amuron et al. 2009; Bassett et al. 2009).
Turning late presenters into ‘early presenters’ – patients
who enrol in pre-ART care and monitoring programs
before becoming eligible for ART – requires a sequence of
linked services and high retention of patients at each
transition phase. This sequence starts with HIV testing,
continues to CD4 testing and referral to a care program for
those not ART eligible, proceeds to the patient making
regular clinic visits for monitoring, and ends at ART
initiation. Loss to follow up (LTFU) at any of these steps
results in late presentation for treatment. We have
estimated the rate of LTFU between initial enrolment in
pre-ART care for patients not yet eligible for ART (baseline
CD4 > 250 cells⁄ll) and their ﬁrst scheduled return visit at
one of South Africa’s largest HIV⁄AIDS treatment facili-
ties. This analysis complements related studies that address
lost to follow up for patients who are eligible for ART but
do not initiate ART (Lawn et al. 2005, 2006; Amuron
et al. 2009; Bassett et al. 2009).
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Study site and population
Themba Lethu Clinic (TLC) is the HIV⁄AIDS Compre-
hensive Care Management and Treatment (CCMT) facility
at Helen Joseph Hospital (HJH) in Johannesburg. As of
May 2009, >13 000 patients were actively on ART at TLC.
The clinic is funded by the Gauteng Department of Health,
with additional support from the President’s Emergency
Plan for AIDS Relief (PEPFAR) and the United States
Agency for International Development (USAID) through
Right to Care, a South African non-governmental organi-
zation (NGO).
At the time of initiating ART at TLC, patients had a
median CD4 count of 98 cells⁄ll during 2007–2008, with
25% having a CD4 count <34 cells⁄ll (personal commu-
nication: M. Maskew). These ﬁgures are consistent with
ﬁndings reported for other sites in South Africa and sub-
Saharan Africa (Egger 2007).
In South Africa’s public sector, ART eligibility is deﬁned
as a CD4 count £200 cells⁄ll or a WHO Stage IV
condition. At the site, patients with CD4 counts £200
cells⁄ll are referred to the ART treatment program as well
as patients with CD4 counts between 201 and 250. Those
with higher counts (CD4 > 250) are not referred for
treatment but instead are referred to the pre-ART care and
monitoring program. Patients who enrol in pre-ART care
have already made at least two visits to the clinic or
elsewhereforHIV-relatedservices—oneforHIVtestingand
CD4 count and a second for receiving CD4 count results.
Data collection
At TLC, enrolment in pre-ART care occurs for patients
with a baseline CD4 count >250 cells⁄ll upon returning to
the clinic for a day of wellness counselling that provides
information on a range of topics including living with HIV,
information on available social services, and nutrition. The
clinic records a new patient’s ﬁrst visit to the wellness
program in a logbook. The next step in pre-ART care is to
return to the clinic for a ﬁrst follow-up medical visit with a
primary health care nurse. Patients are scheduled to return
for this visit at 3 months if their enrolment CD4 count is
250–350 cells⁄ll or at 6 months if their enrolment CD4
count is >350 cells⁄ll.
Wellness logbooks were reviewed to identify all new
patients enroling in pre-ART care at TLC from January
2007 to February 2008. Patient records were reviewed in
June 2009 to determine whether each subject returned for
their ﬁrst medical visit. Visit dates and demographic
information from patient records were also recorded.
Censoring of the dataset in June 2009 provided a minimum
follow-up of 15 months for all subjects. Patients with a
baseline CD4 count £ 250 cells⁄ll were not included in this
analysis because they are managed differently in prepara-
tion for ART initiation.
The study received ethical approval from Boston
University and the University of the Witwatersrand.
Statistical analysis
Patients with CD4 counts of 250–350 cells⁄ll were
scheduled to return at 12 weeks. For these patients, we
deﬁned two primary outcomes: whether or not the subject
returned to TLC (1) within 4 and 40 weeks of their
scheduled return appointment (16 week and 52 week total
return period after enrolment). We also deﬁned two
primary outcomes for patients with CD4 counts >350 who
were scheduled to return at 24 weeks: whether or not the
subject returned to TLC within 12 and 28 weeks of their
scheduled return appointment (36 and 52 week total
return period after enrolment). Crude proportions of
patients completing their ﬁrst return medical visit based on
these primary outcomes were calculated.
We estimated directly relative risks of returning for CD4
results within 1 year using the modiﬁed Poisson approach
developed by Zou (2004). A log-binomial approach can
also be used for estimating relative risks directly, although
the approach may estimate standard errors that are too
small and convergence problems may occur (Mcnutt et al.
2003). A simple Poisson approach, on the other hand, is
known to provide estimates of standard errors that are too
large (Zou 2004). The modiﬁed Poisson approach simply
applies a standard Poisson model with robust standard
errors. The relative risk model includes the following
patient-speciﬁc factors as potential confounders (age, sex,
marital and employment status, and baseline CD4 count).
Results
A total of 544 patients were newly enrolled in the TLC pre-
ART care program during the study period. We excluded 41
patients who enrolled in the program but did not have an
enrolment CD4 count and 147 patients indicated in the log
bookasnotyeteligibleforART,butwhowerelaterfoundto
haveaCD4count£250cells⁄llatenrolmentasthesepatients
were not early presenters. This left 356 patients for analysis.
Figure 1 summarizes the crude proportions stratiﬁed
by baseline CD4 count of patients (expressed as percent-
ages) that were loss to follow up. Of the 356 total patients,
128 (36%) presented with a CD4 count £350 cells⁄ll
(median [IQR] = 296 [278–313]). These patients were
counselled to return within 3 months for their ﬁrst medical
visit. Eight (crude proportion 6%; 95% CI 2.3%–11.5%)
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proportion 35.2%; 95% CI 27.3%–43.7%) returned
within 1 year, and the remaining 75 (crude proportion
59%; 95% CI 50.0%–67.0%) did not return within a year.
The other 228 patients (64%) enrolled with a CD4
count >350 cells⁄ll (median [IQR] = 458 [394–585]) and
were counselled to return within 6 months for their initial
medical visit. Of these, 33 (crude proportion 14.5%; 95%
CI 10.3%–19.5%) completed the visit within 9 months,
26 (crude proportion 11.4%; 95% CI 7.7%–16.0%)
within a year and the remaining 169 (crude proportion
74%; 95% CI 68.1%–79.5%) did not return within a
year (Figure 1).
Table 1 provides basic summary information on key
patient characteristics stratiﬁed by those who returned
within one year and those who did not. In both groups,
median age was 35 years, 21% were married, and about
25% were men. A higher proportion of patients who
returned within one year were employed (57% compared
to 44%). The median CD4 count was lower for patients
who returned within one year than for those who did not
(354 compared to 403).
Relative risks based on the modiﬁed Poisson model are
reported in Table 2. Baseline CD4 count and employment
status were signiﬁcant predictors of returning for the ﬁrst
medical visit. Compared to the group with the lowest
baseline CD4 count (251–350 cells⁄ll), the risks of
returning within 1 year dropped substantially (RR: 0.66;
95% CI: 0.46–0.96) when the baseline CD4 count was
351–450 cells⁄ll and 0.61 (95% CI 0.42–0.88) for
Table 1 Descriptive statistics for those
who returned for the ﬁrst care program
medical visit within 52 weeks and those
who did not (% unless otherwise speciﬁed)
Variable
Returned within
52 weeks
Did not return
within 52 weeks P-value*
Age (median [IQR]) 35 [30, 42] 35 [30, 42] 0.68
Employed 57% 44% 0.02
Male 24% 27% 0.55
Married 21% 21% 0.94
CD4 (median [IQR] 354 [301, 455] 403 [321, 550] 0.01
*P-value for t-test of equality of sample means (in this case proportions) assuming unequal
variances or non-parametric two-sample test on the equality of medians (using t-test and
median command in Stata 10.1).
356 patients enrolled in wellness program 
with a 1st CD4 count > 250
CD4 count 251–350
counseled to return within
12 weeks (n = 128)
median [IQR] CD4 count =
296 [278, 313] at enrollment
CD4 count 351+
counseled to return within
24 weeks(n = 228)
median [IQR] CD4 count =
458 [394, 585] at enrollment
Returned within
16 weeks
(n = 8)
Returned between
17–52 weeks
(n = 45)
Returned within 36 
weeks (n = 33)
Returned between 
37–52 weeks (n = 26)
Did not return 
within 52 weeks
(n = 75)
Did not return 
within 52 weeks
(n = 169)
% 4 6 % 6 3
6%
35%
59%
15%
11%
74%
Figure 1 Lost to follow up among patients newly enrolled in pre-ART HIV care (did not return for ﬁrst care program medical visit).
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employed patients (RR 1.41; 95% CI 1.03–1.92) vs.
unemployed patients.
Discussion
In this study, 69% of patients enrolled in pre-ART care
failed to return for their ﬁrst medical visit within 1 year of
enrolment. This highlights the need for greater investment
in patient retention from the beginning of HIV care, not
just after ART begins.
Our data, combined with a previous analysis of post-
voluntary counseling and testing (VCT) rates of CD4
testing at the same site (Larson et al. 2009), paint a striking
picture. First, very few patients (13%) who learn their
HIV status prior to ART eligibility return to the clinic to
obtain their CD4 counts (Larson et al. 2009). Second, we
showed only a small proportion of pre-ART care patients
return for their ﬁrst medical visit on time; less than 1⁄3
of these patients return within 1 year of enrolment.
According to the HIV⁄AIDS and STI Strategic Plan for
South Africa, 2007–2011 (South African National Depart-
ment of Health), South Africa aims to ‘provide an appro-
priate package of treatment, care and support services to
80% of HIV positive people and their families by 2011 in
order to reduce morbidity and mortality as well as other
impacts of HIV⁄AIDS’ (South African National Depart-
ment of Health, p. 57). One of the main goals of pre-ART
care is to monitor disease progression to ensure as early a
start on ART as possible, hopefully before the patient
develops serious clinical illness. The low rate of retention
we observed at the very beginning of the HIV care program
does not bode well for achieving the country’s stated goal.
Patients who do not even return for their ﬁrst medical visit
may have beneﬁted by being made aware of their status and
from the counselling that accompanied the HIV test and
CD4 count, but they are still at risk of becoming late
presenters. Pre-ART care thus remains a broken link in the
chain that should connect HIV testing to ART through pre-
ART care. This link must be repaired if the problem of late
presentation for treatment is to be solved and South Africa
is to meet its national policy goals.
This study had several limitations. It was conducted at
only one facility in South Africa, albeit one of the largest,
so it is possible that experience differs at other sites.
Importantly, there is no medical information system in
South Africa that allows patients to be tracked from one
facility to another. We cannot therefore rule out the
possibility that some of our subjects transferred to a care
program elsewhere, though this is unlikely to explain more
than a fraction of the high level of attrition we observed.
Finally, we do not know why the subjects in our study did
or did not return. It is possible that some patients with low
CD4 counts who should have returned within 3 months
but instead waited 9–10 months, returned because they
were sick and needed medical care. Patients like these, who
can no longer accurately be labelled ‘early presenters,’ may
cause our results to overestimate the proportion of patients
who adhered to the program schedule.
None of these limitations is sufﬁcient to alter the core
ﬁnding of this study, which is that the majority of patients
are lost from pre-ART care between enrolment and their
ﬁrst return visit. Future research is needed to examine why
patients are LTF in pre-ART care and what interventions
are feasible and effective for reducing such losses. We
suspect that barriers to returning for pre-ART program
visits are similar to barriers to ART adherence in general,
which include, but are not limited to, costs and⁄or time for
transport, lost earnings, lack of ﬁnancial resources, stigma,
lack of family support, perceived need and psychological
issues (Jones 2005; Mshana et al. 2006; Horne et al. 2007;
Kinsler et al. 2007; Makombe et al. 2007; Muula et al.
2007; Wilson & Blower 2007). Employed patients were
substantially more likely to complete their return medical
visit within one year than unemployed patients, which is
consistent with the literature on barriers to ART adherence
Table 2 Relative risks of returning for the
ﬁrst medical visit*
Returned 52 weeks Relative Risk P-value
95% Conﬁdence
Interval
Age 1.005 0.517 0.990 1.020
Employed 1.408 0.031 1.032 1.922
Male 0.834 0.332 0.578 1.203
Married 0.939 0.746 0.643 1.371
cd4 251–350   
cd4 351–450 0.661 0.028 0.457 0.956
cd4 451+ 0.606 0.009 0.417 0.883
*Relative risk estimated based on Poisson regression with robust standard errors in STATA
10.1 following Zho (Zou 2004), adjusted for age, employed, male, married, and CD4
categories speciﬁed in the previous table.
The reference case.
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these barriers for particular patient populations and
seeking strategies for overcoming them.
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